After an information-packed, week-long program of short courses, conference sessions, and poster presentations, CHI’s 10th Annual PEGS Summit officially came to a close on May 9 in Boston.
With a record attendance of 1800+ participants from over 30 countries, attendees took advantage of the copious networking opportunities. The exhibit hall was the central gathering place for participants to connect and form new collaborations, while the breakout discussion groups provided a casual environment for open discussions to address industry trends, perspectives and challenges. It was knowledge-sharing at its best.
Plenary Keynotes Peter CR Emtage, Ph.D., Vice President of Immune Mediated Therapies at MedImmune and George D. Yancopoulos, M.D., Ph.D., President of Regeneron Laboratories kicked-off the event with dynamic presentations and captivated the audience to set the tone for the high-caliber presentations delivered throughout the week.
We would still like to hear from you on more specific questions to help us deliver new ideas, and develop the agenda and schedule for 2015. To send us your feedback, and input for next year’s event, please contact Christina Lingham at Clingham@healthtech.com
SAVE THE DATE to join us again next year May 4-8 in Boston!
20 Conferences, 375+ Speakers, 1,800+ Participants,
175+ Posters, 100+ Exhibitors, 1 Location - Be a Part of It!
Over 1,600 participants will gather in Boston’s vibrant seaport district for open forum discussions and collaboration at CHI’s flagship biologics event “PEGS the essential protein engineering summit”. The continued success of PEGS is driven by the growth in biologics worldwide, the quality of scientific programming presented and valuable networking opportunities.
2014 Event Features Include:
1,600+ 1,800 Participants
- 20 Conferences
- 15 Short Courses
- 375+ Presentations
- 100+ Exhibitors
- 175+ Posters
Plenary Keynote Speakers
Peter CR Emtage, Ph.D., Vice President, Immune Mediated Therapies, MedImmune
George D. Yancopoulos, M.D., Ph.D., President, Regeneron Laboratories; CSO, Regeneron Pharmaceuticals, Inc.